Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) CEO Bobak R. Azamian sold 6,000 shares of the company's stock in a transaction on Monday, March 24th. The shares were sold at an average price of $50.00, for a total value of $300,000.00. Following the completion of the sale, the chief executive officer now directly owns 824,106 shares in the company, valued at $41,205,300. This trade represents a 0.72 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Tarsus Pharmaceuticals Stock Performance
Shares of TARS stock opened at $51.01 on Thursday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The firm has a market capitalization of $1.96 billion, a price-to-earnings ratio of -13.39 and a beta of 1.05. Tarsus Pharmaceuticals, Inc. has a one year low of $20.08 and a one year high of $57.28. The company has a 50 day moving average price of $48.82 and a 200 day moving average price of $45.82.
Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, beating analysts' consensus estimates of ($0.68) by $0.08. The firm had revenue of $66.41 million for the quarter, compared to analysts' expectations of $58.80 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. Sell-side analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.
Analysts Set New Price Targets
Several research analysts recently issued reports on the company. Guggenheim restated a "buy" rating and set a $78.00 price objective (up from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. HC Wainwright reaffirmed a "buy" rating and set a $73.00 price objective on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 26th. Oppenheimer boosted their target price on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research note on Wednesday, January 22nd. Barclays decreased their price target on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Finally, Jefferies Financial Group boosted their price objective on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Tarsus Pharmaceuticals presently has a consensus rating of "Buy" and an average price target of $63.67.
Check Out Our Latest Report on Tarsus Pharmaceuticals
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the business. Crowley Wealth Management Inc. purchased a new position in shares of Tarsus Pharmaceuticals in the 4th quarter valued at $25,000. GF Fund Management CO. LTD. acquired a new position in shares of Tarsus Pharmaceuticals during the fourth quarter worth about $44,000. R Squared Ltd purchased a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter worth about $53,000. Quarry LP acquired a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter valued at about $166,000. Finally, HighTower Advisors LLC purchased a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter valued at about $207,000. Hedge funds and other institutional investors own 90.01% of the company's stock.
About Tarsus Pharmaceuticals
(
Get Free Report)
Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
